Clik here to view.
Over 1 Million People Have Been Treated with New Hepatitis Drugs, But Cost...
More than 1 million people have now received hepatitis C treatment using the new highly effective and well-tolerated direct-acting antiviral agents despite their high cost, according to a report...
View ArticleClik here to view.
HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates
Use of generic versions of direct-acting antivirals for hepatitis C resulted in very high cure rates for people who obtained the products through 3 buyers’ clubs, indicating that the generic products...
View ArticleClik here to view.
Coverage of IDWeek 2016
HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans. Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic...
View ArticleClik here to view.
IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6...
A new 3-drug regimen of sofosbuvir, ledipasvir, and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated patients with all...
View ArticleClik here to view.
AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But...
People who are cured of hepatitis C after a course of direct-acting antiviral treatment do not have a higher risk of developing hepatocellular carcinoma (HCC) -- and probably have a reduced risk --...
View ArticleClik here to view.
AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match...
Direct-acting antiviral treatment is curing people of hepatitis C in real-world clinical practice at similar rates to those seen in clinical trials, and there do not seem to be major differences...
View ArticleClik here to view.
AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for...
A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV)...
View ArticleClik here to view.
AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with...
AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 hepatitis C patients -- those with cirrhosis or previous treatment experience --...
View ArticleClik here to view.
AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV...
AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in 3 large clinical trials covering 5 out of 6 genotypes of the virus, and it is likely to receive...
View ArticleClik here to view.
AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6...
A 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated patients with all hepatitis...
View ArticleClik here to view.
AASLD 2016: U.S. Veterans Health System and Australia Show Potential for...
If sufficient money is available to pay for direct-acting antivirals (DAAs), the U.S. Veterans Health Administration could cure hepatitis C in the majority of veterans under its care within 3 years,...
View ArticleClik here to view.
Coverage of the 2016 AASLD Liver Meeting
HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016. Conference highlights include direct-acting...
View ArticleClik here to view.
AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for...
A new 3-drug coformulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2, or 3, with...
View ArticleClik here to view.
AASLD 2016: Primary Care Providers Can Effectively Treat Patients with...
Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment...
View ArticleClik here to view.
AASLD 2016: Hepatitis C Virus Infection Rising Among Gay Men in San Diego
The prevalence of hepatitis C virus (HCV) infection among HIV-positive men who have sex with men in San Diego has increased over the past 15 years, especially among men who do not inject drugs but use...
View ArticleClik here to view.
AASLD 2016: Non-Adherence Is Most Important Risk Factor for...
Research carried out by researchers at Mount Sinai Medical Center in New York found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir...
View ArticleClik here to view.
AASLD 2016: 6 Weeks of Sofosbuvir/Ledipasvir Cures Genotype 1 Acute Hepatitis C
A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads,...
View ArticleClik here to view.
AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with...
AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 hepatitis C patients -- those with cirrhosis or previous treatment experience --...
View ArticleClik here to view.
AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression
People who achieved sustained virological response to interferon-based hepatitis C treatment experienced significantly less decline in kidney function, especially if they had liver cirrhosis,...
View ArticleClik here to view.
AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with...
A 2-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for chronic hepatitis C patients with severe kidney impairment, according to...
View Article